HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takita, H. Articles by Dougherty, T. J. Search for Related Content PubMed PubMed Citation Articles by Takita, H. Articles by Dougherty, T. J.

The Annals of Thoracic Surgery, Vol 58, 995-998, Copyright © 1994 by The Society of Thoracic Surgeons

ARTICLES

Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study

H Takita, TS Mang, GM Loewen, JG Antkowiak, D Raghavan, JR Grajek and TJ Dougherty
Division of Thoracic Surgery and Oncology (Department of Surgical Oncology), New York State Department of Health, Roswell Park Cancer Institute, Buffalo.

From April 1991 to May 1993, 23 patients entered a phase II clinical study of surgical resection and adjuvant intracavitary photodynamic therapy for malignant pleural mesothelioma. Two days preoperatively, patients received an intravenous injection of 2 mg/kg of the photosensitizer Photofrin. Six patients underwent a pleuro- pneumonectomy, and 15 patients a pleurectomy, after which intracavitary photodynamic therapy was administered. A total light energy dose of 20 to 25 J/cm2 was given. In 2 patients the tumor was unresectable due to intrapericardial invasion. Postoperative complications were noted in more than 50 percent of patients; 2 patients died of postoperative complications. Postoperative survival was analyzed according to intraoperative staging proposed by the American Joint Committee for Cancer Staging, published in 1992. The overall estimated median survival is 12 months; that of stage III and IV patients is 7 months. Five patients with stage I and II diseases (who had grossly complete resection by pleurectomy) are alive, disease-free, for 11, 17, 18, 21, and 33 postoperative months. Intraoperative staging is important in carrying out further clinical studies of malignant pleural mesothelioma.

This article has been cited by other articles:

				H. Schouwink, E. T. Rutgers, J. van der Sijp, H. Oppelaar, N. van Zandwijk, R. van Veen, S. Burgers, F. A. Stewart, F. Zoetmulder, and P. Baas Intraoperative Photodynamic Therapy After Pleuropneumonectomy in Patients With Malignant Pleural Mesothelioma : Dose Finding and Toxicity Results Chest, October 1, 2001; 120(4): 1167 - 1174. [Abstract] [Full Text] [PDF]

				E. G. Butchart Contemporary Management of Malignant Pleural Mesothelioma Oncologist, December 1, 1999; 4(6): 488 - 500. [Abstract] [Full Text]

				J. R. Roberts Surgical Treatment of Mesothelioma: Pleurectomy* Chest, December 1, 1999; 116(suppl_3): 446S - 449S. [Abstract] [Full Text] [PDF]

				D. H. Sterman, L. R. Kaiser, and S. M. Albelda Advances in the Treatment of Malignant Pleural Mesothelioma Chest, August 1, 1999; 116(2): 504 - 520. [Abstract] [Full Text] [PDF]

				T. L. Moskal, T. J. Dougherty, J. D. Urschel, J. G. Antkowiak, A.-M. Regal, D. L. Driscoll, and H. Takita Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up Ann. Thorac. Surg., October 1, 1998; 66(4): 1128 - 1133. [Abstract] [Full Text] [PDF]

				D. B. Campbell Malignant Mesothelioma Ann. Thorac. Surg., May 1, 1997; 63(5): 1503 - 1505. [Full Text]

				J. D. Luketich, J. Westkaemper, K. E. Sommers, P. F. Ferson, R. J. Keenan, and R. J. Landreneau Bronchoesophagopleural Fistula After Photodynamic Therapy for Malignant Mesothelioma Ann. Thorac. Surg., July 1, 1996; 62(1): 283 - 284. [Abstract] [Full Text]